AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10526939
Drug: Nitrate infusion
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate infusion for 48 hours (group B)
Trial: 10526939
Drug: Nitrate infusion
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate infusion for 78 hours (group C)
Trial: 7481324
Drug: Combined local
RxNorm normalized name: Local hemostatic combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined local treatment (surgery plus radiotherapy)
Trial: 31821466
Drug: Zinc bis-glycinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc bis-glycinate (15 mg elemental zinc), twice per day
Trial: 24007754
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg given by mouth)
Trial: 21311047
Drug: Health promotion
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health promotion intervention (patient education, health promotion coaching, medication management, physician care management)
Trial: 11072398
Drug: 21 mg/day
RxNorm normalized name: nicotine 21 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg/day nicotine patch
Trial: 11072398
Drug: 35 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg/day nicotine patch
Trial: 11072398
Drug: 42 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 mg/day nicotine patch
Trial: 11072398
Drug: 0 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/day nicotine patch (control)
Trial: 7564894
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg caffeine/kg lean body mass
Trial: 2207419
Drug: Potassium 60
RxNorm normalized name: potassium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium 60 mmol/day in combination with magnesium 20 mmol/day
Trial: 7461014
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of digoxin 1.25 mg
Trial: 7461014
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of digoxin 0.625 mg
Trial: 7461014
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of digoxin 0.25 mg
Trial: 7461014
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose of digoxin 0.125 mg
Trial: 31836261
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin 40UI
Trial: 24857519
Drug: LNAA tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNAA tablets plus supplementation with tryptophan (Trp) and tyrosine (Tyr) tablets
Trial: 24857519
Drug: LNAA tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LNAA tablets plus placebo
Trial: 17616778
Drug: Entrée portion
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entrée portion size of 500 g and energy density of 1.8 kcal/g
Trial: 17616778
Drug: Entrée portion
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entrée portion size of 250 g and energy density of 1.3 kcal/g
Trial: 15222514
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and combined technique of physical therapy
Trial: 25654309
Drug: Sham/unsuccessful bronchoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham/unsuccessful bronchoscopic treatment (Control, n = 10)
Trial: 17109595
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate (600 microg) and biotin (2 mg/day)
Trial: 11739451
Drug: Ghrelin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ghrelin infusion (0.1 microg/kg.min)
Trial: 3557711
Drug: Verapamil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.1 mg/kg as a bolus followed by chronic infusion of 0.005 mg/kg/min for 3 min, intravenously)
Trial: 22508203
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (1.5 μg/kg body weight)
Trial: 22508203
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA with Piritramide
Trial: 20723651
Drug: Candesartan 32
RxNorm normalized name: candesartan 32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 32 mg 1 time/day
Trial: 15673877
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tramadol and morphine
Trial: 12919771
Drug: Dronedarone 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone 800 mg daily
Trial: 12919771
Drug: Dronedarone 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone 1600 mg daily
Trial: 6261677
Drug: Prednisolone, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, starting dose 60 mg daily
Trial: 6261677
Drug: Prednisolone, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 10 mg/kg in rats
Trial: 21118875
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of Edmonston‐Zagreb measles vaccine at 4.5 and 9 months of age (group A)
Trial: 21118875
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of Edmonston‐Zagreb measles vaccine at 9 months of age (group B)
Trial: 21118875
Drug: Schwarz measles
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz measles vaccine at 9 months of age (group C)
Trial: 15662518
Drug: Atypical antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotic drugs
Trial: 10073377
Drug: Conventional antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antipsychotic drugs
Trial: 9129531
Drug: EchiTab (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EchiTab (one vial, 10 ml; 0.5 g protein)
Trial: 9129531
Drug: Institute Pasteur
RxNorm normalized name: Human fibrinogen concentrate, pasteurized
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Institute Pasteur Serum (Ipser) Africa antivenom (four ampules, 40 ml; 2.12 g protein)
Trial: 3286518
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg/b.i.d.)
Trial: 3286518
Drug: Cefalexin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefalexin (1 g/t.i.d.)
Trial: 20639624
Drug: Bisphosphonates (BPs)
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates (BPs) treatment
Trial: 12372131
Drug: FP 200
RxNorm normalized name: PEANUT ALLERGEN-DNFP 200MG (LEVEL 9) POWDER,ORAL,PKT,30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 200 microg/day (constant dose group)
Trial: 10669910
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (GFJ) with 300 mg of phenytoin (DPH)
Trial: 10669910
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with 300 mg of phenytoin (DPH)
Trial: 8960728
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon beta-1b (8.0 million units)
Trial: 8960728
Drug: Low-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose interferon beta-1b (1.6 million units)
Trial: 2012909
Drug: Day-hospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day-hospital treatment
Trial: 7044656
Drug: Attempted improved
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attempted improved therapy (A group)
Trial: 7044656
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy (U group)
Trial: 26374297
Drug: Extended-release niacin/laropiprant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin/laropiprant (ERN/LRP)
Trial: 25401325
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 100 mg/d
Trial: 22833639
Drug: Posaconazole tablet
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole tablet 200 mg once daily
Trial: 22833639
Drug: Posaconazole tablet
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole tablet 200 mg twice daily
Trial: 22833639
Drug: Posaconazole tablet
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole tablet 400 mg once daily
Trial: 17767075
Drug: Aprotinin (10,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (10,000 KIU test dose, 2 million KIU load, 0.5 million KIU per hour)
Trial: 15164290
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of different tests
Trial: 9696955
Drug: Caffeine (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (4.5 mg. 1(‐1) and 9 mg. 1(‐1))
Trial: 9696955
Drug: Theophylline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (3 mg. 1(‐1), 6 mg. 1(‐1), and 12 mg. 1(‐1))
Trial: 9696955
Drug: Caffeine and
RxNorm normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine and Theophylline (all doses)
Trial: 7511070
Drug: Farmorubicin (FARM)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Farmorubicin (FARM) at a dose of 72 mg/body
Trial: 7511070
Drug: Adriamycin (ADR)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADR) at a dose of 48 mg/body
Trial: 3947524
Drug: Nebulizer therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 8 litres/min
Trial: 3947524
Drug: Nebulizer therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 6 litres/min
Trial: 3947524
Drug: Nebulizer therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer therapy with salbutamol (1 mg in 2 ml of physiological saline) driven by piped oxygen at 4 litres/min
Trial: 29114907
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg) intravenous infusion at day 0 and at 12 months
Trial: 20302588
Drug: 1-week quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Trial: 20302588
Drug: 2-week quadruple
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week quadruple therapy (tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., esomeprazole 20 mg b.i.d.)
Trial: 20302588
Drug: 1-week quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week quadruple therapy
Trial: 20302588
Drug: 2-week quadruple
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week quadruple therapy
Trial: 9411543
Drug: Drug-free regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free regimen
Trial: 9411543
Drug: Liver necrosis
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver necrosis index (for drug-free regimen)
Trial: 30958831
Drug: SCBSCT‐BA (Cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCBSCT‐BA (Cognitive-behavioral smoking cessation treatment with behavioral activation)
Trial: 30958831
Drug: SCBSCT (Standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCBSCT (Standard cognitive-behavioral treatment)
Trial: 30256095
Drug: Combined water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined water treatment, sanitation, handwashing (WSH)
Trial: 25294886
Drug: FOLFOX ±
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX ± cetuximab therapy
Trial: 19606688
Drug: Follow-up ultrasound
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up ultrasound evaluation after successful treatment of basic diseases
Trial: 11564001
Drug: Buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30 mg)
Trial: 11573063
Drug: Glucose 33%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 33% solution
Trial: 11573063
Drug: Glucose 5%
RxNorm normalized name: Glucose 5% Nursette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 5% solution
Trial: 8113846
Drug: Sequential treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment: cisplatin 100 mg/m2 over 15 minutes on day 1 plus 5‐FU 1.0 g/m2 by continuous infusion on days 1 to 5, followed by 70 Gy of radiation in 7 to 8 weeks.
Trial: 8113846
Drug: Concomitant treatment:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment: cisplatin 60 mg/m2 over 15 minutes on day 1 plus 5‐FU 800 mg/m2 by continuous infusion on days 1 to 5 plus radiation 2 Gy on days 1 to 5, repeated every other week for seven cycles.
Trial: 27134145
Drug: Concomitant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant treatment
Trial: 8113846
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment and Concomitant treatment
Trial: 26059709
Drug: 0·9% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0·9% sodium chloride sterile solution
Trial: 25680887
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker (CCB) group: losartan 50 mg plus amlodipine 5 mg
Trial: 25680887
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor (ACEI) group: enalapril 5 mg
Trial: 25680887
Drug: Thiazide diuretic
RxNorm normalized name: Thiazide diuretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide diuretic (HCTZ) group: hydrochlorothiazide 12.5 mg
Trial: 25680887
Drug: Control period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control period (usual dose of ARB)
Trial: 23966328
Drug: Low-fat milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat milk (475 mL)
Trial: 21910712
Drug: 1450 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1450 nm laser treatment (Candela Smoothbeam laser); 3 treatments performed monthly, using a double-pass technique, 6 mm spot size, 210 ms pulse duration, fluence of 8 or 9 J cm(‐2)
Trial: 21910712
Drug: 1450 nm
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1450 nm laser treatment
Trial: 18939389
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (hemoglobin A1c target 7.0% to 7.9%)
Trial: 17023867
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (MPH-IR) at 2.5 mg t.i.d.
Trial: 17023867
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (MPH-IR) at 5 mg t.i.d.
Trial: 17023867
Drug: Immediate-release methylphenidate
RxNorm normalized name: methylphenidate Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release methylphenidate (MPH-IR) at 7.5 mg t.i.d.
Trial: 17023867
Drug: Best-dose MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best-dose MPH
Trial: 10079408
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI) (n = 126 oocytes)
Trial: 7307036
Drug: Miconazole tampons
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miconazole tampons (2 tampons daily for 5 days)
Trial: 7307036
Drug: Clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole vaginal tablets (1 tablet daily for 6 days)
Trial: 30902692
Drug: Bacterial keratitis
RxNorm normalized name: hepatitis nosodes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacterial keratitis treatment
Trial: 15182379
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care provided by community pharmacists after training
Trial: 9400878
Drug: Consultation-liaison psychiatry
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consultation-liaison psychiatry service (C-L) referrals without symptom-matched controls (n = 27)
Trial: 9400878
Drug: Symptom-matched C-L
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-matched C-L referrals
Trial: 9808859
Drug: Sublingual glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual glyceryl trinitrate (GTN)
Trial: 7622910
Drug: IL-1 receptor
RxNorm normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-1 receptor antagonist (IL-1ra)
Trial: 22777396
Drug: Emotional demands
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emotional demands (unfair treatment, client's family abuse)
Trial: 21710402
Drug: yohimbine (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine (0.4 mg/kg)
Trial: 15529514
Drug: Metformin-glibenclamide combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin-glibenclamide combination tablets (Glucovance)
Trial: 2851443
Drug: CEP/MEC chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEP/MEC chemotherapy (cyclophosphamide 500 mg/m2 i.v. day 1; epirubicin 50 mg/m2 i.v. day 1; cisplatin 80 mg/m2 i.v. day 1; alternated with methotrexate 30 mg/m2 i.v. day 1; etoposide 200 mg/m2 i.v. day 1; CCNU 70 mg/m2 per os, day 1) until progression.
Trial: 30921804
Drug: Subcutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunotherapy (SCIT) with house dust mite extract
Trial: 28673214
Drug: TAP catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP catheter (18 ml 0.5% ropivacaine every four hours)
Trial: 28673214
Drug: PRS catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRS catheter (18 ml 0.5% ropivacaine every four hours)
Trial: 28673214
Drug: SC catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC catheter (18 ml 0.5% ropivacaine every four hours)
Trial: 21255767
Drug: 10‐week web‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐week web‐based unguided self‐help treatment for social phobia
Trial: 21255767
Drug: 10‐week web‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐week web‐based self‐help treatment with minimal weekly therapist support via email
Trial: 21255767
Drug: 10‐week web‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐week web‐based self‐help treatment with flexibly stepped-up support (email or telephone contact on demand)
Trial: 19298412
Drug: prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prulifloxacin 600 mg
Trial: 12765806
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 units every 12 hours, SC, for 7 days)
Trial: 10983362
Drug: Amitriptyline (12.5-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (12.5-25 mg/daily)
Trial: 10983362
Drug: Fluoxetine (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10-20 mg/daily)